The objective of this study is to determine whether pharmacokinetic parameters of anidulafungin correlate with disease severity and plasma protein levels in critically ill patients.
One of the risk factors for mortality of patients with candidemia is inadequate antifungal therapy. The first days in the intensive care unit (ICU), patients are unstable and it can be questioned whether therapeutic levels of anidulafungin are reached after a standard loading scheme. At this moment there are several clues that the PK of anidulafungin in critically ill patients is different, but an overall picture is lacking. For the investigation of the correlation of the pharmacokinetics of anidulafungin and the disease severity a full pharmacokinetic profile will be obtained. Predictive scoring systems will be used to assess disease severity.
Study Type
OBSERVATIONAL
Enrollment
20
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands
To investigate the correlation of pharmacokinetic parameters of anidulafungin with markers for disease severity - either disease severity scores or parameters (singly, or combined) for inflammation or organ function - and plasma protein levels.
Time frame: 3 days
Time (in days) to culture conversion
Time frame: max 28 days
Response to treatment at day 28
Time frame: 28 days
Mortality at day 28 due to fungal infection and overall mortality at 28 days
Time frame: 28 days
AUC/MIC ratio, time above MIC
Time frame: max 28 days
Composing a pharmacokinetic model of anidulafungin in critically ill patients
Time frame: max 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.